HealthMore in Health→
Novo Nordisk Partners With MIT-Backed Startup to Develop Oral Obesity Drugs
Key Takeaways
- Novo Nordisk deals with Vivtex to develop oral alternatives to injectable obesity and diabetes drugs
- Vivtex was co-founded by MIT's Robert Langer, also a Moderna co-founder
- Oral delivery could massively expand the GLP-1 market beyond injection-averse patients
- Competes with Eli Lilly and others racing to develop pill-form GLP-1 treatments
DE
DT Editorial Team··4 min read·via statnews.com